

Co-Sponsored by J.P.Morgan | Johnson Johnson INNOVATION

## The Future of Partnering: Evolving Opportunity Despite Uncertainty

7:30 a.m. –	Monday, May 9, 2022 (All times in Eastern Standard Time)  1:1 Partnering Open
8:00 p.m.	· ·
4:00 p.m. – 7:00 p.m.	In-Person Networking Reception*  Join us at an In-Person Networking Reception at The Liberty House in Jersey City.
	Tuesday, May 10, 2022
7:30 a.m. – 8:30 a.m.	1:1 Partnering Open
8:30 a.m. – 9:00 a.m.	Welcome & Opening Remarks  • Debbie Hart, President & CEO, BioNJ
, , , , , , , , , , , , , , , , , , ,	<ul> <li>David Jimenez, MBA, AMP, President Janssen US Immunology, Janssen Pharmaceutical</li> </ul>
	Companies of Johnson & Johnson  • Kathryn McDonough, Managing Director, Co-Head, Healthcare, Commercial Banking, J.P. Morgan  Time Collinson Chief Franchis Officer Name Lawrence Franchis Boundary and Authority (AUEDA)
9:00 a.m. –	• Tim Sullivan, Chief Executive Officer, New Jersey Economic Development Authority (NJEDA) Industry Overview: Biopharma and Surrounding Landscape - Key Trends & Outlook
9:30 a.m.	What's next after a challenging year, including thoughts around drivers of M&A and healthcare VC capital investment.
9:30 a.m. –	Robbie Huffines, MBA, Global Chairman, Investment Banking, J.P. Morgan  Navigating the Economic Impact on Healthcare Companies Through Uncertainty
10:00 a.m.	How will labor shortages, supply-chain disruptions, increased oil prices and geopolitics impact the industry and the broader economy?
	• Jim Glassman, Ph.D., MBA, Managing Director, Head Economist, Commercial Banking, J.P. Morgan
10:00 a.m. – 10:45 a.m.	Engaging Partners and Investors in Today's More Challenging Market  An open discussion on best practices in today's challenging environment of rationalization of
	price, valuation and risk; partnering with large pharma; attracting VCs or partners; as well as the importance of lead investor, later-stage assets and scientific merits.
	Panelists:  • Vineet Agarwal, MBA, Chief Financial Officer, Korro Bio, Inc.
	<ul> <li>Allison Fritts, Sr. Director, Immunology Corporate Development, The Janssen Pharmaceutical Companies of Johnson &amp; Johnson</li> </ul>
	<ul> <li>Sam Hall AB, MPhil, Ph.D., Life Sciences Venture Investor &amp; Entrepreneur</li> <li>David Ke, Managing Director, Equity Capital Markets, J.P. Morgan Investment Bank</li> </ul>
10:45 a.m. –	Moderator: John Whittaker, MBA, Managing Director, J.P. Morgan  Break
11:00 a.m.	
11:00 a.m. – 12:30 p.m.	Start-Up/Pitch Presentations Entrepreneurs from both early stage companies as well as academic spinouts will be live in a Zoom
	Room to chat and present their innovations. Investors, potential partners and other Conference attendees can observe and interact with the entrepreneurs.
11:00 a.m. – 12:30 p.m.	Company Presentations Entrepreneurs from later-stage companies will be live in a Zoom Room to chat and present their
	innovations. Investors, potential partners and other Conference attendees can observe and interact with the entrepreneurs.
12:30 p.m. – 12:45 p.m.	Break
12:45 p.m. –	Diversity, Equity & Inclusion (DEI) in Clinical Trials Panel
1:30 p.m.	Industry experts will discuss key considerations on the road to success in achieving health equity in clinical trials, including the critical need to build trust, data collection, language, home healthcare
	and telehealth.  Panelists:
	<ul> <li>Kate Owen, Senior Vice President, Global Development Operations, Bristol Myers Squibb</li> <li>Darshak Sanghavi, M.D., Global Chief Medical Officer, Babylon Health</li> </ul>
	<ul> <li>Craig Tendler, M.D., Global Head, Late Development, Diagnostics &amp; Medical Affairs,</li> <li>Hematology, Oncology, Janssen Pharmaceutical Companies of Johnson &amp; Johnson</li> </ul>
	Moderator:  • Marion Brooks, MBA, Vice President & U.S. Country Head, Diversity & Inclusion, Novartis
1:30 p.m. – 2:15 p.m.	Addressing the Patent Imbalance: Women & Patents  Data are dismal, but improving, on the numbers of patents coming from mostly female biomedical
	research teams — just 16.2% — up from 6.3% in 1976. Experts will discuss success strategies to improve these statistics.
	Panelist:  • Elodie Carpentier, Ph.D., Research Fellow, Invent Together
	<ul> <li>Forough Ghahramani, EdD, MBA, MS, Associate Vice President, Research, Innovation and Sponsored Program, NJEdge</li> </ul>
	<ul> <li>Valencia Martin-Wallace, JD, Deputy Commissioner for Patents, United States Patent &amp; Trademark Office (USPTO)</li> </ul>
	<ul> <li>Judith A. Sheft, MBA, Executive Director, New Jersey Commission of Science Innovation &amp; Technology (NJCSIT)</li> </ul>
	Moderator:  • Terri Shieh-Newton, Ph.D., Member, Mintz
2:15 p.m. –	Closing Remarks
2:30 p.m. 2:30 p.m. –	Peruse Company Pages, Visit Institution Alley, Watch Presentations on Demand,
8:00 p.m.	Schedule/Conduct 1:1 Partnering Meetings and Talk with Others in the Public Forum
7:30 a.m. –	Wednesday, May 11, 2022
8:30 a.m.	1:1 Partnering Open
8:30 a.m. – 8:45 a.m.	Welcome & Opening Remarks  • Debbie Hart, President & CEO, BioNJ
	Sarah Brennan, Vice President Janssen US Commercial Strategy Organization,     Janssen Pharmaceutical Companies of Johnson & Johnson
8:45 a.m. –	Kristine O'Keefe, MBA, CFA, CFP, Executive Director, J.P. Morgan     Innovative Ecosystems to Bring Transformative Healthcare Solutions to Patients
9:30 a.m.	Innovation ecosystems – enabling and empowering innovators across a broad healthcare spectrum including pharmaceutical, medical device, consumer and health tech sectors to create
	and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to Patients around the world.
9:30 a.m. –	• Fiona Mack, Ph.D., Head of JLABS @ TMC, Johnson & Johnson Innovation, JLABS  Drug Pricing Policy Proposals and the Dangers for Funding, Innovation and Patient Access
10: 15 a.m.	Patients are paying too much for healthcare. As a result, healthcare affordability is on the lips of policymakers everywhere. As policies are developed to address this reality, it is important to
	protect innovation and Patient access. Economic and other experts will discuss the potentially devastating consequences of certain policy proposals on innovation and access and the need to
	consider the role of the entire healthcare continuum on cost.  Panelists:
	<ul> <li>Gary Branning, MBA, Professor, Pharmaceutical Management, Rutgers Business</li> <li>School &amp; President, Managed Market Resources, LLC</li> </ul>
	<ul> <li>Richard Evans, Ph.D. MPPM, General Manager, SSR Health LLC</li> <li>John Michael O'Brien, PharmD, MPH, President &amp; CEO, National Pharmaceutical Council</li> </ul>
	<ul> <li>Duane Schulthess, CEO, Vital Transformation LLC</li> <li>Moderator:</li> </ul>
	<ul> <li>Michele M. Oshman, Vice President, External Affairs, Executive Director, Council of State Bioscience Associations, Biotechnology Innovation Organization (BIO)</li> </ul>
10:15 a.m. – 10:30 a.m.	Break
10:30 a.m. –	Pain Points in Clinical Trials Clinical trials have undergone significant change during COVID-19. Many of which will continue
11:15 a.m.	Clinical trials have undergone significant change during COVID-19. Many of which will continue into the future. Our panel will discuss diversity in trials; decentralized, in-home and streamlined trials and the impact for the future of drug development; as well as the implementation of key
	trials and the impact for the future of drug development; as well as the implementation of key learnings and takeaways from COVID-19.
	<ul> <li>Panelists:</li> <li>Michael King, MHSc, Ph.D., Senior Director, Diabetes Project Leader, Sanofi</li> <li>Lauren S. Litzinger, MS, Process, Standards and Signal Interpretation Group Lead,</li> </ul>
	<ul> <li>Lauren S. Litzinger, MS, Process, Standards and Signal Interpretation Group Lead,</li> <li>Global Site and Study Operations, <i>Pfizer</i></li> <li>David MacMurchy, CEO, <i>Lightship</i></li> </ul>
	Moderator:
11:15 a.m. –	<ul> <li>Paul I. Howard, Ph.D., Senior Director of Public Policy, Amicus Therapeutics</li> <li>Break</li> </ul>
11:30 a.m. 11:30 a.m. –	Company Presentations
1:00 p.m.	Entrepreneurs will be live in a Zoom Room to present and discuss their innovations. Investors,

entrepreneurs.

Break

Panelists:

**Moderator:** 

panel. Panelist:

Panelist:

1:00 p.m. –

1:15 p.m. 1:15 p.m. –

2:00 p.m.

2:00 p.m. –

2:45 p.m. –

7:30 a.m. –

7:30 a.m. –

8:00 p.m.

8:00 p.m.

3:00 p.m.

2:45 p.m.

During this fireside chat, entrepreneurs representing successful spinouts from world-renowned

• David Greenwald, Ph.D., Vice President, Business Development, Deerfield Management

NGS and targeted medicine are revolutionizing drug development and creating unprecedented

hope for rare disease and other Patients. Hear more on the future of this promising area of scientific discovery and how entrepreneurs can capitalize on the promise during this important

• Scott Palmer, MA, Ph.D., Director, Business Development, Janssen Pharmaceutical

• Jane Li, MBA, Global Director, Global Companion Diagnostics Commercialization

Thursday, May 12, 2022

Friday, May 13, 2022

potential partners and other Conference attendees can observe and interact with the

Fireside Chat: Academic Medical Institution Spinout Successes

• Scott Kachlany, Ph.D., Founder, Actinobac Biomed, Inc. • Jason Rifkin, JD, MS, President & CEO, PhageNova

• Amy Liao, Ph.D., Chief Executive Officer, Couragene Inc.

and CRO Partnership, Thermo Fisher Scientific

Join us in a Zoom Room to connect with other attendees.

Companies of Johnson & Johnson

**Networking & Closing Remarks** 

1:1 Partnering Open

1:1 Partnering Open

institutions will discuss their path to success and the pitfalls along the way.

Next Generation Sequencing (NGS) & Impact on Drug Development